Analysis: Investors weigh chaos as high court reviews health law

A patient waits in the hallway for a room to open up in the emergency room at Ben Taub General Hospital in Houston, Texas, July 27, 2009. REUTERS/Jessica Rinaldi

A patient waits in the hallway for a room to open up in the emergency room at Ben Taub General Hospital in Houston, Texas, July 27, 2009.

Credit: Reuters/Jessica Rinaldi

By Lewis Krauskopf

NEW YORK | Thu Mar 22, 2012 6:21pm EDT

NEW YORK (Reuters) – At Aetna Inc’s headquarters in Hartford, Connecticut, about two dozen employees devote all their working hours to one task: making sure the health insurer is up to speed with President Barack Obama’s U.S. healthcare overhaul law.

On a part-time basis, more than 1,000 more employees are also working daily on activities tied to the overhaul as the No. 3 U.S. health insurer seeks to comply with the regulations and communicates the changes to its thousands of customers.

In 2010 alone, Aetna says it invested 53,000 work hours — the equivalent of one person working for 25 years — updating computer systems to accommodate the new benefits and changes in the law.

“This is touching every different type of business we have,” Kay Mooney, Aetna’s head of strategic development and product who is helping oversee the company’s overhaul efforts, said in an interview. “We need to think about it in all respects.”

What if all the work is for naught? That possibility comes into high relief for the healthcare industry starting on Monday, when the U.S. Supreme Court begins hearing arguments about the healthcare overhaul law.

And it has investors and analysts attempting to handicap fallout from the high-profile decision. Shares of large health insurers appear to face little significant downside should the law be entirely tossed out or upheld — at least in the near term. The major risk lies with a decision that strikes down just the part of the law that requires people to buy coverage.

The court is expected to rule by late June on the law — Obama’s signature domestic policy achievement enacted two years ago that is set to extend health coverage to more than 30 million uninsured Americans. The law is being challenged by 26 states and an independent business group.

At the heart of the court debate is the portion that requires individuals to buy health insurance or pay a penalty. Should the court strike down that requirement, known as the individual mandate, and deem it unseverable from the rest of the law, the entire legislation would be invalidated.

“We will have chaos,” said Timothy Jost, a law professor who focuses on healthcare at the Washington and Lee University School of Law in Virginia.

Such chaos may not be bad news for investors in the short term. Many healthcare analysts say shares of large insurers, such as Aetna, UnitedHealth Group Inc and WellPoint Inc stand to immediately jump at least 5 percent should the court strike down the legislation as a whole.

Others see a more modest insurer share rally possible if the law is upheld as a decision will provide more certainty over how the companies will do business. But most agree that a partial ruling that tosses out just the individual mandate could be disastrous for the stocks.

The law’s regulations put greater scrutiny on the insurance premium increases that help fuel industry profits. They require insurers to spend at least 80 percent of their premiums on medical costs as opposed to administrative expenses and impose higher fees on their insurance plans in the years ahead.

“The best case is if the whole thing gets thrown out,” said Tim Nelson, healthcare analyst with Nuveen Asset Management.

But that sentiment has not been shared by many insurance executives since the law was passed in 2010. Several have expressed their opposition to Republican efforts to repeal the law. If the Supreme Court shoots it down now, the problems of Americans lacking insurance and the country’s rising healthcare costs will remain — possibly forcing government to intervene with far more onerous regulations on the industry in the future.

“What the marketplace needs is some certainty as to where healthcare reform is going,” said Robert Laszewski, who consults for health insurers as president of Health Policy and Strategy Associates. “And while the Obama health law is so imperfect and flawed in so many ways, it gave us a target and it said here’s where we’re going to be for the next 10 or 20 years.”

Among other industries, shares of hospital chains, such as HCA Holdings Inc and Tenet Healthcare Inc, are expected to drop steeply should the law be struck down because they would stand to lose millions of insured customers.

Such a ruling is poised to boost shares of medical device manufacturers, such as Boston Scientific, which face taxes on sales of their products under the law.

STATUS QUO SEEN LIKELY

In an American Bar Association poll of a small group of influential academics, journalists and lawyers who follow the Supreme Court, 85 percent predicted the law would be upheld.

More than 70 percent of 200 investors queried by Goldman Sachs in January also speculated that a decision to uphold the law would be the most likely outcome.

Still, shares of health insurers could rise modestly should the law win backing. Some investors may have held off on the sector until the court’s decision provides more certainty.

“If it’s status quo, there’s probably a rally,” said Les Funtleyder, a portfolio manager and healthcare strategist with Miller Tabak. “It’s probably also a rally for hospitals too.”

The worst-case scenario for health insurers is if the court strikes down the individual mandate but leaves the rest of the law standing. Wall Street experts see this as unlikely.

The law requires insurers to offer coverage regardless of health status, including pre-existing medical conditions. To counter the likely influx of sick, high-cost policyholders, insurers say the individual mandate is necessary to ensure that healthy people are also in the insurance pool.

If only the mandate is struck down, many people may only buy insurance when they become ill, said Justine Handelman, vice president of legislative and regulatory policy for the Blue Cross and Blue Shield Association.

“It’s akin to saying you can buy your homeowners insurance when you smell smoke,” Handelman said. “That will cause premiums to go up for everyone.”

Health insurer stocks would also tumble, possibly more than 5 percent, said David Heupel, senior healthcare analyst at Thrivent Investment Management.

The court is also weighing whether the federal government unconstitutionally forced the states to expand the Medicaid program to millions more low-income Americans under the law.

The expansion could provide an important growth opportunity for some big players like UnitedHealth as well as smaller insurers that specialize in Medicaid, such as Amerigroup, Molina Healthcare and Centene.

“We believe Medicaid’s expansion … is the one that carries a meaningful risk of being overturned,” analysts at Jefferies & Co said in a recent research note. “Such a decision would be a meaningful negative for most healthcare service stocks, especially acute care providers and managed Medicaid companies.”

Meanwhile, Aetna and other insurers continue to operate as if the law will stay in place — unless they learn otherwise.

“We have strategies ready for whatever happens over the next 18 months,” Mooney said.

(Editing by Michele Gershberg; desking by Mark Porter)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints


Read more from the original source
Analysis: Investors weigh chaos as high court reviews health law

:, , , , , , , , , ,

Related Article(s)

Preparation

Before operation, please inform us if there are any allergies or serious medical conditions. Also please inform us all medication that you are taking.

Please contact us if you need any pick up on your arrival at the airport. We can help you reserve the hotel room and other arrangement if necessary.

However please inform us your flight itinerary one week before your arrival.

Post Operative Care

- No doctor's fee if any corrections are required.
- All post-operative aftercare is provided without cost.

If you have any question please contact us.


Preis.

Bitte klicken Sie hier für den Kostenvoranschlag zu bitten.

Zahlung

Wir akzeptieren Überweisung, Kreditkarten und Bargeld. Für weitere Informationen über Zahlungsmethoden bitte kontaktieren Sie uns .

Flughafen Immigration and Customs.

Bitte legen Sie die Unterlagen zur Bestätigung der geplanten Operation auf Anfrage. Bitte tragen keine unnötigen Medikamente oder gefährliche Gegenstände in Ihrem Gepäck.     

Termin mit Surgeon.

Bitte klicken Sie hier. einen Termin vereinbaren oder kontaktieren Sie uns für weitere Informationen.

Die Preise für unseren Service bereits enthalten (falls nötig).

1. Praxisgebühr.

2. Beitrag Betrieb Gebühr.

3. Medikamente gegen Gebühr.

4. Krankenhausaufenthalt Gebühr (falls nötig).

5. Anästhesie-Gebühr.

6. Labortest Gebühr.

7. Kostenloser Abholservice von der Luft-Port / Hotel.

8. Kosten der OP.

9. Doktor Gebühr.

>> Hotels in der Nähe SP-Klinik.




Skin Procedures
"Good bacteria" during pregnancy may ward off eczema
2009 swine flu outbreak was 15 times deadlier: study
A pill that treats and tells
Abusing pain drug Opana can cause blood disorder: FDA
Acupuncture has limited benefit for chronic pain
Acupuncture may help some people with COPD: study
Alzheimer’s death rate higher in former NFL players
Amish farm kids remarkably immune to allergies: study
Analysis links psoriasis, diabetes
Analysis: Beleaguered beef purveyors carve out "pink slime" stain
Analysis: Employees to face healthcare sticker shock
Analysis: GSK bolsters medicine chest with biotechnology buy
Analysis: Investors plot hedges for healthcare law ruling
Analysis: Investors weigh chaos as high court reviews health law
Anti-obesity proposal fails again at McDonald’s
Antibiotics prevent UTIs better than probiotics
Arizona governor signs law banning most late-term abortions
Artery injury signs common in pro volleyballers
As circumcision rates drop, costs increase: study
Ask all women about abuse, says task force
Ask women about partner violence, panel says
AstraZeneca wins EU approval for new antibiotic
Aveo kidney cancer drug more tolerated than Nexavar
Bangladesh’s "teenage" brothels hold dark steroid secret
Banned sex workers find sympathy from AIDS meeting organizers
Barney, Kung Fu Panda help kids get warts off
Benefits of circumcision outweigh risks, U.S. pediatrics group says
Berlin clears ritual circumcisions ahead of new law
Bird flu outbreak hits chicken farms in Mexico
Blasting music tied to drinking and drugs: study
Botox
Botox may help multiple sclerosis tremors
British anthrax death sparks outbreak concern
California tobacco tax measure risks going up in smoke
Can patient photos help cut medical errors?
Canada OKs Osiris drug; first stem cell therapy
Cancer patients rarely speak up about care problems
Carboxytherapie
Celgene psoriatic arthritis drug effective in trial
Celgene’s Abraxane meets main goal in melanoma trial
Child addicts at heart of Indonesia anti-smoking suit
Chronic stress tied to worse heart attack prognosis
Climate linked to California ER visits
Coca-Cola, Sanofi team for new line of "Beautific" drinks
Coffee not linked to psoriasis
Common nose implant has high infection rate: study
Contraceptive pill, ring tied to higher stroke risk
Dauerhafte Haarentfernung
Deep belly fat may increase after liposuction
Doctors try to make sense of cancer’s genetic jumble
Drugmakers seek EU deal to keep supplies flowing
Drunk drivers show risky lifetime drinking habits: study
Dyax halts mid-stage study of rare disease drug
Energy drink makers face NY state probe
Epilepsy drug leads to weight loss, side effects
Exclusive: German drug firm Stada’s failed Russian forays
Exclusive: GSK set for Human Genome takeover – sources
Exercise tied to lower risk of psoriasis: study
Exercise, vitamin D may prevent falls: guidelines
Extra vitamin D may not help ward off colds
Facing anti-malaria nets, mosquitoes alter habits: study
Fake drugs hard to spot amid 1,800 UK wholesalers
FCC may take up issue of cell phone radiation
FDA advisers back Cameron Health heart device
FDA approves Boston Scientific’s unique heart device
FDA approves Teva leukemia drug
FDA delays deadline for new U.S. sunscreen labels
FDA rejects expanded use of Regeneron drug for gout
FDA says nanotech may need extra safety tests
FDA says number of new drug shortages down
FDA says reviewing its email spying program
FDA staff doubt Cameron device better than rivals
FDA warns about Mexicali brand products on listeria concerns
FDA warns Avon to smooth out claims on skin care products
FDA warns of burns from muscle and joint pain busters
Few options if top court strikes part of health law
Free birth control tied to drop in abortions
French health body favors reimbursement of InterMune lung drug
Glaxo melanoma drug combo shows promise in small trial
Glaxo melanoma drugs beat chemo in pivotal trials
GlaxoSmithKline, J&J to start rheumatoid arthritis drug trial
Global health group seeks to "save brains" as well as lives
Graying America gets wired to cut healthcare costs
GSK submits melanoma drugs in U.S., Europe
Gum disease linked to psoriasis: study
Gynecologists alarmed by plastic surgery trend
Hand deformities turn up in poultry workers: report
Hand, foot and mouth disease kills 17 in China – Xinhua
Having a resident in on surgery is safe: study
Having a trainee surgeon in operations is safe -study
Health group attacks Gatorade’s Michael Jordan ad
Health groups sue U.S. for failing to protect food supply
Health panel: Pap tests needed only every 3 years
Hearing test benefits unknown in older adults: panel
Homöopathie
Hormone boosts mental function in small study
Hot water, not pee, eases jellyfish stings
HPV vaccine found safe in large study
Implants may help prevent repeat teen pregnancies
In the Age of Anxiety, are we all mentally ill?
 

 


Awarded by
WhatClinic.com
 

SP Clinic 1519/69-70 Ladproud 41/1 Samsennog Huaykuang Bangkok 10310, Thailand
Mobile Phone For English please call + 6681 915 1030
Tel. +662 9304450-5 Fax. +662 9399061
 
email: spsansiri@yahoo.com       drsompob@sp-cosmeticsurgery.net
 
Website Designed, and Developed by RedOnion Co.,Ltd.